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Mitochondrial Pyruvate Carriers are not Required for
Adipogenesis but are Regulated by High-Fat Feeding
in Brown Adipose Tissue
Jasmine A. Burrell1,2, Allison J. Richard

2,

William T. King3, and Jacqueline M. Stephens

Objective: The objectives of this study were to assess the role of mitochondrial pyruvate carriers (MPCs) in adipocyte development in vitro and
determine whether MPCs are regulated in vivo by high-fat feeding in male
and female C57BL/6J mice.
Methods: This study utilized small interfering RNA-mediated knockdown
to assess the requirement of MPC1 for adipogenesis in the 3T3-L1 model
system. Treatment with UK-5099, a potent pharmacological MPC inhibitor, was also used to assess the loss of MPC activity. Western blot analysis was performed on adipose tissue samples from mice on a low-fat diet
or a high-fat diet (HFD) for 12 weeks.
Results: The loss of MPC expression via small interfering RNA-mediated
knockdown or pharmacological inhibition did not affect adipogenesis
of 3T3-L1 cells. In vivo studies indicated that expression of MPCs was
significantly decreased in brown adipose tissue of male mice, but not
female, on an HFD.
Conclusions: Although MPCs are essential for pyruvate transport, MPCs
are not required for adipogenesis in vitro, suggesting that other substrates
can be used for energy production when the MPC complex is not functional. Also, a significant decrease in MPC1 and 2 expression occurred in
brown fat, but not white fat, of male mice fed an HFD.

1,2

Study Importance
What is already known?
► Mitochondrial pyruvate carriers (MPCs)
are essential for pyruvate to be transported into the mitochondria and
utilized as substrate by the pyruvate

dehydrogenase complex for energy
production.

What does this study add?
► This study is novel because it demonstrates that MPCs are not required for
the adipogenesis of 3T3-L1 cells, suggesting that other substrates may compensate for energy production during in
vitro adipogenesis.
► This study is also novel because it
shows that MPCs are regulated by
diet-induced obesity in brown adipose
tissue.

Obesity (2020) 28, 293-302.

Introduction
The mitochondrial pyruvate carriers (MPCs) are transmembrane proteins, found on the inner mitochondrial membrane, that transport pyruvate from the cytosol into the mitochondrial matrix where pyruvate is
oxidized to acetyl coenzyme A (acetyl CoA) and carbon dioxide via the
pyruvate dehydrogenase complex. Acetyl CoA is utilized in the citric
acid cycle to form reduced nicotinamide adenine dinucleotide (NADH)
for oxidative phosphorylation to create a proton gradient for the production of ATP via the ATP synthase complex. There are two MPC proteins
in mammals (MPC1 and MPC2), but there are three that have been
identified in Saccharomyces cerevisiae (MPC1, MPC2, and MPC3) (1).
In mammals, MPC1 and MPC2 form a heterodimer to actively transport
pyruvate into the mitochondria (2). Because MPC1 and MPC2 act in a
codependent manner, the loss or deletion of one of these proteins results
in the loss of the other MPC because of destabilization (2-4). The study

of MPC1 mutants has confirmed that dimerization of MPC1 and MPC2
in the inner mitochondrial membrane is essential for pyruvate uptake
into the mitochondria (3).
MPC1 expression may also play a role in cancer metabolism as inhibition of MPC complex formation, via UK-5099, hinders pyruvate’s entry
into the mitochondria and is associated with increased glycolysis (5).
Increased glycolysis is a distinct metabolic feature of cancer cells, along
with mitochondrial reprogramming and decreased lipid metabolism (6).
The MPC inhibitor 2-Cyano-3-(1-phenyl-1H-inodl-3-yl)-2-propenic
acid (UK-5099) binds to MPCs, which deactivates the MPC complex
and inhibits pyruvate oxidation (7). Thiazolidinediones inhibit MPCs in
several cell types, and in skeletal muscle, inhibition of MPCs is associated with increased glucose uptake and increased insulin sensitivity.
Using the CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) system, a heterozygous
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MPC1 knockdown model was generated, and these mice had reduced
lipid accumulation, increased lipolysis, enhanced fatty acid oxidation,
and decreased energy expenditure (8). During adipogenesis, mitochondrial density is increased by 20- to 30-fold along with increases in
mitochondrial gene expression and oxidative capacity to meet increasing energy requirements (9-13). Insufficient or reduced mitochondrial
density in tissues with a high energy demand (such as the brain, heart,
and muscles) and endocrine organs (such as adipose tissue) is associated
with disease states (14). Although MPCs have been studied in several
cell and tissue types, the role of these proteins in adipocyte development
and their regulation in conditions of obesity are not known.
In our novel studies, we examined the requirement of MPC1 during
adipocyte development using two independent approaches. Both pharmacological inhibition of MPCs as well as small interfering RNA (siRNA)-mediated knockdown of MPC1 demonstrated that the expression
and/or activity of MPC1 was not required for adipogenesis in 3T3-L1
cells. To our knowledge, this is the first siRNA-mediated MPC1 knockdown reported in 3T3-L1 cells. However, siRNA-mediated knockdown
of MPC1 and MPC2 in 832/13 β-cells resulted in impaired insulin secretion in response to glucose and reductions in glucose-stimulated oxygen
consumption (15). We also examined the modulation of MPC expression in both brown (BAT) and white adipose tissue (WAT) depots of
male and female mice in a rodent model of diet-induced obesity (DIO).
Expression levels of MPC1 and MPC2 were substantially decreased in
the BAT of male mice following high-fat feeding, but not in female mice
under the same conditions. In conclusion, our results indicate that loss
of MPC1 does not have any effect on adipogenesis of 3T3-L1 preadipocytes, MPC1 and MPC2 are highly expressed in BAT, and MPC1 and
MPC2 are modulated by high-fat feeding in BAT of male mice.

Methods
Animals and diets
Four-week-old male and female C57BL/6J mice were purchased from
Jackson Laboratories (Stock #000664; Bar Harbor, Maine). Animals
were housed in a temperature-controlled (22°C ± 2°C) and humiditycontrolled (45%-55%) room under a 12-hour light/dark cycle. At 6 weeks
of age, mice were placed on respective diets. Mice were allowed ad
libitum access to food and water. For 12 weeks, mice had access to
either a low-fat diet (LFD) containing 20% of kilocalories from protein,
70% of kilocalories from carbohydrate, and 10% of kilocalories from
fat (D12450J; Research Diets, Inc., New Brunswick, New Jersey) or a
high-fat diet (HFD) containing 20% of kilocalories from protein, 20%
of kilocalories from carbohydrate, and 60% of kilocalories from fat
(D12492; Research Diets). Body weights were obtained biweekly. Mice
were fasted for 4 hours prior to euthanasia. All animal studies were performed with approval from the Pennington Biomedical Research Center
Institutional Animal Care and Use Committee.

Animal body composition and glucose tolerance
measurements
Nonfasting body composition was measured by nuclear magnetic resonance (NMR) (Bruker Minispec, Bruker BioSpin Corp., Billerica,
Massachusetts) at 6 weeks of age (before beginning LFD or HFD intervention) and at 19 weeks of age (after 12 weeks of LFD or HFD
feeding). Adiposity was calculated as total fat mass ÷ total body
weight × 100. Following a 4-hour fast, an intraperitoneal glucose tolerance test (GTT) was performed on each animal at 17 weeks of age (10
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weeks on diet). A baseline blood glucose measurement was obtained
via tail nick (0 minutes), and animals were then injected with 2.5 g/
kg of glucose. Blood glucose measurements were obtained via a drop
of blood collected from the tail vein at 20, 40, 60, and 120 minutes post
injection. Blood glucose measurements were performed using a Breeze
2 glucometer (Bayer, Parsippany, New Jersey).

Cell culture
Murine 3T3-L1 preadipocytes were grown in DMEM (Sigma-Aldrich, St.
Louis, Missouri) with 10% bovine calf serum. Two days after confluence,
the preadipocytes were induced to differentiate using a standard protocol
and induction cocktail composed of MDI cocktail (3-isobutyl-1-methylxanthine [IBMX], dexamethasone, insulin) and 10% characterized fetal
bovine serum (FBS) in DMEM. HyClone bovine calf serum and FBS
were purchased from Thermo Scientific (Waltham, Massachusetts) or GE
Healthcare Life Sciences (Marlborough, Massachusetts). The medium
was changed every 48 to 72 hours during growth and differentiation.

Pharmacological inhibitor (UK-5099) treatments
3T3-L1 preadipocytes were trypsinized and seeded into six-well plates at
a density of 5.8 × 105 cells/cm2 in antibiotic-free 10% bovine calf/DMEM
when approximately 70% confluent in 10-cm plates. 3T3-L1 preadipocytes were treated with 10µM UK-5099 (Sigma-Aldrich; PZ0160) added
to the medium upon seeding. Preadipocytes were induced to differentiate as previously described. Cells were fed with antibiotic-free media
and treated with UK-5099 every 48 hours. Seven days after the induction
of differentiation, the cell monolayers were harvested for protein in immunoprecipitation (IP) buffer containing 10mM Tris (pH 7.4), 150mM
NaCl, 1mM EGTA, 1mM EDTA, 1% Triton X-100, 0.5% IGEPAL CA630 (octylphenoxypolyethoxyethanol), protease inhibitors (1mM phenylmethylsulfonyl fluoride [PMSF], 1μM pepstatin, 50 trypsin inhibitory
milliunits of aprotinin, 10μM leupeptin, and 1mM 1,10-phenanthroline),
and phosphatase inhibitors (0.2mM sodium vanadate and 100µM sodium
fluoride) and were harvested for RNA in buffer provided in the RNeasy
Mini Kit (Qiagen, Hilden, Germany) to assess knockdown efficiency.
Three biological and technical replicates were analyzed for each dose.
All reagents used to make the IP buffer were from Sigma-Aldrich.

Cytotoxicity and cell viability assays
The ToxiLight BioAssay Kit (Lonza, Cologne, Germany) was utilized
according to the manufacturer’s protocol. ToxiLight 100% lysis reagent
(Lonza) was utilized as a positive control. Cell viability was assessed by
counting trypan blue-stained cells using a hemacytometer.

Whole-cell extract preparation
Cell monolayers were rinsed once with phosphate-buffered saline
(PBS) and then scraped into non-denaturing IP buffer. The whole-cell
extracts were stored at −80°C before being thawed and passed through
a 20-gauge needle five times. The whole-cell extract was clarified via
centrifugation at 13,000g for 10 minutes at 4°C.

siRNA-mediated knockdown
3T3-L1 preadipocytes were trypsinized and replated in six-well plates
at a density of 5.8 × 105 cells/cm2 in antibiotic-free 10% bovine calf/
DMEM when approximately 70% confluent in 10-cm plates. Using the
protocol from Dharmacon, preadipocytes were transfected with 33nM
siRNA (Dharmacon, Lafayette, Colorado; nontargeting siRNA Cat#:
D-001810-10-50, siRNA targeting MPC1 Cat#: L-040908-01-0005) and
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the DharmaFECT Duo transfection reagent (Dharmacon; Cat#: T-201003) in Opti-MEM reduced serum medium (Thermo Fisher, Waltham,
Massachusetts; Cat#: 31985088). Nontargeting siRNA was used as a negative control. Cells were treated with the siRNA cocktail during initial
plating and grown to confluence. Two days after confluence, cells were
induced to differentiate with the MDI induction cocktail, as previously described, and transfected again with the siRNA cocktail. After 48 hours,
the cells were treated with one-quarter normal dose of insulin and transfected once again with the siRNA cocktail. Cells were fed every 48 hours
with antibiotic-free media throughout the entire knockdown process.
Seven days after the induction of differentiation, the cell monolayers were
harvested for protein in IP buffer and for RNA in buffer provided in the
RNeasy Mini Kit to assess knockdown efficiency. Three biological and
technical replicates were analyzed for each dose.

Respirometry
Mitochondrial function was assessed by respirometry of intact cells using a
Seahorse XFe24 Analyzer (Agilent Technologies, Santa Clara, California).
Mature 3T3-L1 adipocytes were seeded at 1.0 × 105 cells per well in an
XF24 specialized cell culture microplate that was coated with 0.1% gelatin for 48 hours prior to seeding. Prior to measuring oxygen consumption,
cells were incubated in XF base media, pH 7.4 (Agilent Technologies)
supplemented with 25mM glucose and 2mM L-glutamine at 37°C without
CO2 for 1 hour. After basal oxygen consumption was measured for three
cycles, 1mM sodium pyruvate ± 10µM UK-5099 was injected into each
well. After three additional measurement cycles, 1µM oligomycin, 600nM
carbonyl cyanide p-trifluoromethoxyphenylhydrazone (FCCP), and 5µM
rotenone/antimycin A were serially injected, and oxygen consumption was
measured for three, six, and three cycles, respectively. After the assay was
complete, cells were harvested in radioimmunoprecipitation assay (RIPA)
buffer, and protein concentration was quantified using the bicinchoninic
acid (BCA) assay kit (Sigma-Aldrich; Cat#: BCA1). Oxygen consumption
rate was normalized to micrograms of protein.

Gel electrophoresis and immunoblotting
Protein content of cell extracts was quantified via BCA assay. Samples
were separated on 7.5%, 12%, or 15% sodium dodecyl sulfate (SDS) polyacrylamide gels (acrylamide; National Diagnostics, Atlanta, Georgia;
Cat#: EC-890) and transferred to nitrocellulose membranes (BioRad,
Hercules, California; Cat#: 162-0115) in 25mM Tris, 192mM glycine, and
20% methanol. After the transfer, membrane strips were blocked in 4%
nonfat milk for 1 hour at room temperature and washed with Tris-buffered
saline - Tween 20 (TBS-T) before incubating with primary antibodies
overnight at 4°C. Strips were washed with TBS-T and then incubated with
either anti-mouse or anti-rabbit horseradish peroxidase-conjugated secondary antibodies (Jackson ImmunoResearch, West Grove, Pennsylvania)
for 1 hour. Strips were washed with TBS-T and visualized with enhanced
chemiluminescence (Pierce/Thermo Scientific, Waltham, Massachusetts).

Antibodies
Anti-STAT (signal transducer and activator of transcription) 5A (L-20;
sc-1081; rabbit polyclonal), anti-adipsin (M-120; sc-50419; rabbit polyclonal), anti-STAT3 (C-20; sc-482; rabbit polyclonal), and anti-ERK (extracellular signal-regulated kinase) 1/2 (C-16; sc-93; rabbit polyclonal)
antibodies were purchased from Santa Cruz Biotechnology (Dallas,
Texas). Anti-adiponectin (PA1-054; rabbit polyclonal) antibody was purchased from Thermo Scientific. Anti-MPC1 (14462S; rabbit monoclonal)
and anti-MPC2 (D4I7G; rabbit monoclonal) antibodies were purchased
from Cell Signaling Technology (Danvers, Massachusetts).
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RNA analysis
Total RNA from tissue samples was extracted according to TRIzol manufacturer instructions (Ambion, Carlsbad, California; Cat#15596018). RNA
from tissue or adipocyte monolayers was purified using the RNeasy Mini Kit.
Ten microliters of purified RNA was used for reverse transcription to generate complementary DNA (cDNA) according to the Applied Biosystems
protocol (Applied Biosystems, Foster City, California; Cat#: 4368813).
Complementary DNA was quantified using the real-time quantitative polymerase chain reaction (qPCR) method in a total volume of 10 µL (2 µL DNA
and 8 µL reaction master mix) using an Applied Biosystems 7900HT system
with SDS 2.4 software. qPCR was performed using Takara SYBR Premix
(Takara Bio USA Inc., Madison, Wisconsin) and primers from Integrated
DNA Technologies (Skokie, Illinois). Thermal cycling conditions were as
follows: 2 minutes at 50°C, 10 minutes at 95°C, and 40 cycles of 15 seconds at
95°C; the dissociation stage was 15 seconds at 95°C, 15 seconds at 60°C, and
15 seconds at 95°C. Cyclophilin A (Ppia; also known as peptidylprolyl
isomerase A) and non-POU domain containing octamer binding protein
(Nono) were used as reference genes. The following mouse genes were examined by reverse transcription (RT)-qPCR: oxoglutarate dehydrogenase
(Ogdh), succinate dehydrogenase complex iron sulfur subunit B (Sdhb),
Mpc1, Mpc2, CCAAT/enhancer binding protein, alpha (Cebpa), peroxisome proliferator-activated receptor gamma (Pparg), adiponectin (Adpn),
citrate synthase (Cs), fatty acid binding protein 4 (Ap2), fatty acid synthase
(Fas; also known as TNF receptor superfamily member 6), and adipsin
(Cfd). Primer sequences are shown in Table 1.

Lipid accumulation measurement
Seven days after the induction of differentiation, cells were fixed and
stained with Oil Red O (Sigma-Aldrich) as described previously (16).

Statistical analysis
Statistical analyses were performed using GraphPad Prism software (version 8; La Jolla, California). Differences between groups were calculated
using t tests and two-way ANOVA. Area under the curve (AUC) calculations and standard linear regression analyses were performed to determine
correlations between MPC protein expression and adiposity or GTT AUC.
Results from studies of cultured adipocytes are shown as mean ± SEM.
Results were considered statistically significant when P < 0.05.

Results
Loss of MPC1 has no effect on in vitro
adipogenesis
Prior to determining the potential requirement for MPC1 expression for
adipocyte differentiation, we examined the protein expression of MPC1
and MPC2 over a 7-day adipogenesis time course in 3T3-L1 cells. As
shown in Figure 1, both MPC1 and MPC2 protein expressions were highly
induced during differentiation. The increased expression was apparent
4 days after the induction of adipogenesis (Figure 1A-1B). To assess the
requirement of MPCs on adipogenesis, we used a potent pharmacological inhibitor of MPCs, UK-5099, which acts by binding to MPCs and
modifying a thiol group to prevent the formation of the MPC1 and MPC2
heterodimer, thus reducing pyruvate transport into the mitochondrial matrix (17,18). Preadipocytes were induced to differentiate in the presence
of UK-5099 at various doses. As shown in Figure 2, a range of inhibitor
doses did not inhibit adipocyte differentiation as judged by lipid accumulation with Oil Red O staining (Figure 2A) or adipocyte marker gene
expression (Figure 2B). Three adipogenic markers (Adpn, Ap2, Fas) were
examined to demonstrate adipocyte development.
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TABLE 1 qPCR primer sequences

Gene

Primer 1, 5′-3′

Primer 2, 5′-3′

Cyclophilin A (Ppia)
Non-POU domain containing octamer binding protein (Nono)
Oxoglutarate dehydrogenase (Ogdh)
Succinate dehydrogenase complex, subunit B, iron sulfur (Sdhb)
Mitochondrial pyruvate carrier 1 (Mpc1 )
Mitochondrial pyruvate carrier 1 (Mpc2 )
Adiponectin (Adpn)
Citrate synthase (Cs)
Fatty acid binding protein 4 (Ap2 )
Fatty acid synthase (Fas)
Adipsin (Cfd )
CCAAT/enhancer binding protein, alpha (Cebpa)
Peroxisome proliferator-activated receptor gamma (Pparg)

CCACTGTCGCTTTTCGCCGC
CATCATCAGCATCACCACCA
ATGGGAAAGACCAAAGCTGA
GGAGGGCAAGCAACAGTATC
CAAGGACTTCCGGGACTATC
CCGACTCATGGATAAAGTGGAG
AAAAGGGCTCAGGATGCTACTG
AGAACTCATCCTGCCTCGT
CCCTCCTGTGCTGCAGCCTTT
GGCATCATTGGGCACTCCTT
CGAGGCCGGATTCTGGG
ACAAGAACAGCAACGAGTACC
CGAGTGGTCTTCCATCACGG

TGCAAACAGCTCGAAGGAGACGC
TCTTCAGGTCAATAGTCAAGCC
CCATGCAGCAGGATAGACAT
GCACACAGGATGCACTCGTA
CATCCGCCCACTGATAATCTC
CTAGTCCAGCACACACCAAT
TGGGCAGGATTAAGAGGAACA
CCTGCTCCTTAGGTATCAGATTG
GTGGCAAAGCCCACTCCCACTT
ACCACCAGCTGCCATGGATC
GAGTCGTCATCCGTCACTCC
TCATTGTCACTGGTCAACTCC
TCACAAGAAATTACCATGGTTGAC

Figure 1 MPC1 and MPC2 expression are induced during adipogenesis in 3T3-L1 cells. 3T3-L1 adipocytes
were induced to differentiate using the 3-isobutyl-methylxanthine, dexamethasone, insulin (MDI) cocktail, and
whole-cell extracts were harvested at the indicated time points to assess MPC1 protein expression over a time
course of adipocyte differentiation. (A) Whole-cell extracts (75 µg of protein per lane) were subjected to Western
blot analysis. Adiponectin was utilized as a positive control for adipogenesis. (B) Densitometry quantification
of MPC1 and MPC2 band intensities at the indicated time points. MPC1 and MPC2 band intensities were
normalized to ERK 1/2 (n = 3 pooled 10-cm plates per time point). Experiments were repeated three times on
independent batches of cells.

To examine the efficacy of UK-5099, respirometry experiments were
performed on 3T3-L1 cells to measure oxygen consumption in the presence of pyruvate with or without the addition of the inhibitor. There
were no differences in oxygen consumption observed during baseline
readings after the addition of pyruvate ± UK-5099 or oligomycin. After
the addition of FCCP, the maximal oxygen consumption rates in 3T3L1 cells treated with the inhibitor were significantly reduced compared
with the control (1.167 vs. 3.411 pmol/min/µg protein) (Figure 2C-2D).
Oxygen consumption rates were reduced by UK-5099 in the presence
of the mitochondrial uncoupler, FCCP, likely because of a reduction of
pyruvate substrate entry into the mitochondria. Cell viability and cytotoxicity assays show that UK-5099-treated 3T3-L1 cells had no changes
in cytotoxicity (Figure 2E) or cell viability (Figure 2F) in comparison
with dimethyl sulfoxide (DMSO), which indicates that UK-5099 has no
toxic effects on the cells.
An independent approach using siRNA-mediated knockdown of MPC1
was also performed to examine the role of MPCs on adipogenesis in
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3T3-L1 cells. Despite substantial loss of MPC1 protein expression
(Figure 3A-3B), there were no observed changes in adiponectin protein
expression or lipid accumulation (Figure 3A-3C). Though Mpc1 gene
expression was significantly reduced, mRNA expression of Mpc2 and
adipogenic markers, such as Adpn, Ap2, and Pparg, was not affected
(Figure 3D). Although Cebpa gene expression increased in the absence
of MPC1, this increase did not affect adipogenesis. These data confirm
that loss of MPC1 expression does not have any significant effects on
adipogenesis of 3T3-L1 cells.

MPCs are regulated in adipose tissue of mice
during high-fat feeding
To further study MPCs, we examined MPC1 and MPC2 protein expression in several adipose tissue depots and compared it with other
tissues in mice. As shown in Figure 4, MPC1 and MPC2 were highly
expressed in BAT, heart, liver, and kidneys in C57BL/6J mice. When
directly compared, it was apparent that there were differences in protein
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Figure 2 UK-5099, a pharmacological inhibitor of MPC1, does not inhibit adipogenesis of 3T3-L1 cells. (A,B) 3T3-L1 preadipocytes were induced to differentiate either
untreated or treated with DMSO vehicle or indicated dose of UK-5099 at the time of induction and every 2 days during differentiation. (A) Seven days post induction, cells
were fixed and stained with Oil Red O. Photographs are from the same experiment, and wells (n = 3 wells per treatment) were treated at the same time. (B) Seven days
post induction, RNA was isolated, purified, and subjected to RT-qPCR to measure gene expression of Mpc1, adipogenic markers (adiponectin [Adpn], fatty acid binding
protein 4 [Ap2], and fatty acid synthase [Fas]), and the mitochondrial marker citrate synthase (Cs) (n = 3 wells per treatment). Target gene expression was normalized to the
reference gene, Nono, and data are plotted as fold change over the DMSO control. (C,D) Respirometry experiments were performed to demonstrate the efficacy of the MPC1
inhibitor in mature 3T3-L1 adipocytes. After introducing 1mM pyruvate ± 10µM UK-5099, the oxygen consumption rate (OCR) was measured using a Seahorse XF analyzer
for three cycles prior to performing the mitochondrial stress test using 1µM oligomycin (Oligo), 600nM FCCP, and 5µM rotenone (Rot)/antimycin A (AA). (C) Full respiration
profile showing the mean OCR normalized by the protein content ± SEM for each well (n = 10 wells per treatment). (D) Maximal respiration after the addition of 600nM FCCP
(n = 10 wells per treatment). Data shown are mean OCR of cells treated with pyruvate (P) or pyruvate and UK-5099 (P + I). Panels C and D were analyzed by unpaired t test.
****P < 0.0001 vs. pyruvate control. Experiments were repeated at least twice on independent batches of cells. (E,F) Seven days post induction, UK-5099-treated 3T3-L1
cells were either (E) subjected to cytotoxicity assay via ToxiLight BioAssay Kit or (F) stained with trypan blue and counted to assess cell viability at indicated doses (n = 3 wells
per treatment for a single batch of cells).

expression of MPC1 and MPC2 in some tissues. MPC1 had a much
higher protein expression than MPC2 in the skeletal muscle, in both
the extensor digitorum longus and the gastrocnemius, and in the brain
(Figure 4). Also, the levels of MPC1 and MPC2 expression were low in
all of the WAT depots (Figure 4).
To determine whether MPC expression was regulated by DIO, mice
were placed on either LFD or HFD for 12 weeks. BAT, inguinal WAT
(iWAT), and gonadal/epididymal WAT (gWAT) were harvested and
analyzed in both male and female mice on LFD or HFD. In both male
and female mice, Mpc1 mRNA expression was significantly decreased
in the BAT, iWAT, and gWAT during high-fat feeding of male and
female mice, while Mpc2 mRNA expression was decreased in the
gWAT of males and the BAT and gWAT of females during high-fat
feeding (Figure 5). We also observed an expected decrease in Fas gene
expression during high-fat feeding (19). Protein expression of both
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MPC1 and MPC2 in BAT was significantly reduced in male mice on
an HFD (Figure 6A-6B). This significant decline in MPC1 and MPC2
levels was not observed in the female mice fed an HFD (Figure 6C6D). In iWAT, MPC1 protein expression was extremely low, near the
detection limit, and no changes in protein levels were observed as a
result of HFD feeding (data not shown). These data indicate that MPC
gene expression is downregulated in a depot and sex-specific manner
by high-fat feeding.
Because female C57BL/6 mice are typically less susceptible to
metabolic dysfunction during HFD-induced obesity than their male
counterparts (20-22), we examined the relationships between MPC1
or MPC2 protein expression and adiposity or glucose tolerance.
Protein expression of MPC1 and MPC2 for males significantly correlated with adiposity and GTT AUC for male, but not female, mice
(Figure 7). For the male mice, the linear fits of MPC1 or MPC2 versus
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Figure 3 Knockdown of Mpc1 gene expression with siRNA does not inhibit adipogenesis of 3T3-L1 cells. 3T3-L1 preadipocytes
were transfected with nontargeting (NT) siRNA or MPC1 siRNA upon plating and every 48 hours following induction of
differentiation with MDI cocktail until end point assessments. Protein and gene expression assessments as well as Oil Red
O staining were conducted on the cells at 7 days post MDI. (A) Whole-cell extracts were isolated and 50 µg of protein per
lane was analyzed by Western blot analysis (n = 3 replicate wells per treatment). Adiponectin was utilized as a differentiated
adipocyte marker. (B) MPC1 band intensities were quantified by densitometry and normalized to ERK 1/2 for each treatment.
(C) Cells were fixed and stained with Oil Red O to examine lipid accumulation. (D) RNA was isolated, purified, and subjected
to RT-qPCR to show gene expression of Mpc1, Mpc2, adipogenic markers (adiponectin [Adpn], fatty acid binding protein 4
[Ap2], CCAAT/enhancer binding protein, alpha [Cebpa], and peroxisome proliferator-activated receptor gamma [Pparg]), and
the mitochondrial marker (citrate synthase [Cs], oxoglutarate dehydrogenase [Ogdh], and succinate dehydrogenase complex,
subunit B, iron sulfur [Sdhb]). Data were analyzed by two-way ANOVA. *P < 0.05, **P < 0.01, and ***P < 0.001 vs. NT control
(n = 3 wells per treatment).

Figure 4 MPC1 and MPC2 proteins are highly expressed in brown adipose tissue, liver, and heart. Select
tissues were harvested from a 27-week-old C57BL/6J mouse to assess the tissue distribution of MPC1 and
MPC2 proteins. (A) Tissue samples were homogenized, and 100 µg of total protein per lane was analyzed
by Western blotting. (B) MPC1 and MPC2 band intensities were quantified by densitometry and normalized
to respective ERK 1/2 intensities for each tissue depot. BAT, brown adipose tissue; EDL, extensor digitorum
longus; gastroc, gastrocnemius; gWAT, gonadal white adipose tissue (WAT); iWAT, inguinal WAT; mWAT,
mesenteric WAT; rpWAT, retroperitoneal WAT.

adiposity or GTT AUC had an R2 value of greater than 0.5, and the
slopes were significantly nonzero (P < 0.01), whereas female mice R2
values were less than 0.4, and none of the slopes was significantly
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nonzero. These data show that decreased levels of MPC proteins in
male mice were associated with increased adiposity and decreased
glucose tolerance.
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Figure 5 Steady-state mRNA expression of Mpc1 is substantially decreased in adipose tissue after high-fat feeding
in male and female C57BL/6J mice. Six-week-old C57BL/6J mice were fed either an HFD or LFD (low fat, LF) for 12
weeks ad libitum before euthanizing and collecting tissue. Brown adipose tissue (BAT), inguinal white adipose tissue
(iWAT), and gonadal white adipose tissue (gWAT) samples were homogenized, and RNA was isolated and purified
from each tissue depot for (A) male and (B) female mice. Each sample was subjected to RT-qPCR to show gene
expression of Mpc1, Mpc2, adipogenic markers (Adpn, Ap2, and Fas), adipokine (Adipsin), and the mitochondrial
marker (Cs). Data were analyzed by unpaired t tests. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 vs. LFD
(n = 6 per condition). Each sample was run in duplicate. Target gene expression was normalized to the reference
gene, Ppia, and data are plotted as fold change over the LF control.

Figure 6 MPC1 and MPC2 expression is significantly decreased in the BAT of male mice, but not female, following
high-fat feeding. Six-week-old male and female C57BL/6J mice were fed either a high-fat diet (HFD) or low-fat
diet (LFD) for 12 weeks ad libitum before euthanizing and collecting BAT. Tissue samples were homogenized, and
30 µg of total protein per lane was subjected to Western blot analysis (n = 6 per condition) for (A) males and (C)
females. MPC1 and MPC2 band intensities were quantified by densitometry and normalized to respective STAT3
intensities for each sample; (B) males and (D) females. Data were analyzed by two-way ANOVA. **P < 0.01 vs. LFD.
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Figure 7 Decreased MPC1 and MPC2 protein expression in BAT during DIO correlates with increased adiposity
and decreased metabolic health in male, but not female, mice. (A,B) MPC protein expression from the immunoblot
quantification in Figure 6 was correlated with percent fat mass (adiposity) for male and female mice on LFD and
HFD. Protein extracts were collected and adiposity measured at 19 weeks of age (12 weeks on diet). (C,D) MPC
protein expression values for male and female mice were also plotted against area under the curve (AUC) of glucose
tolerance tests (GTT) performed on LFD- and HFD-fed mice at 17 weeks of age (10 weeks on diet) for male and
female mice. Linear regression analyses were performed and are shown. R2 values indicate goodness of the linear
fit for each data set, and whether the slope is significantly differently from zero is denoted by P value or marked “ns”
(not significant).

Discussion
Our novel data demonstrate the dispensability of MPC1 during adipogenesis in vitro as well as show the expression and modulation of
MPCs in BAT in vivo during DIO. The observed increase in protein
expressions of both MPC1 and MPC2 during adipocyte differentiation
of 3T3-L1 cells (Figure 1) has not been previously reported in 3T3-L1
cells, but MPC1 and MPC2 expression was shown to increase upon
differentiation of leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5)+ intestinal stem cells (23). The increase in MPC1 and
MPC2 expression in adipocytes is likely due to increased mitochondrial
density and gene expression that occurs to generate energy needed to
accommodate the enhanced metabolic requirements during adipogenesis (9,12,13). Because of enhanced protein expression of MPCs during
differentiation, we hypothesized that MPCs were necessary for the differentiation of 3T3-L1 cells.
Contrary to our premise, two independent approaches using both pharmacological inhibition with UK-5099 (Figure 2) and siRNA-mediated
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knockdown (Figure 3) of MPCs did not affect adipocyte development.
Even at doses as low as 50nM, UK-5099 has been able to inhibit formation of the MPC1 and MPC2 heterodimer, thus inhibiting pyruvate
transport via this complex (4,17). In BAT progenitor cells, the addition
of UK-5099 inhibited 13C-glucose incorporation into acetyl CoA (17),
suggesting that the pyruvate produced from glycolysis of 13C-glucose
was not utilized for acetyl CoA production because of impaired pyruvate uptake by the MPC heterodimer via UK-5099 inhibition. Liverspecific loss of MPC2 in C57BL/6J mice resulted in compromised, but
not eliminated, pyruvate metabolism and suggested that mechanisms
such as pyruvate-alanine cycling were activated to compensate for the
loss of the MPC complex functionality (24). A robust decline (~80%)
in MPC1 expression via siRNA knockdown also had no effect on adipocyte development (Figure 3). Our data further support the current literature. Our observations suggest that although pyruvate is the primary
substrate for energy production in the mitochondria, other substrates,
such as alanine, glutamine (2,24,25), or branched chain amino acids
(26), might bypass the MPC1/2 complex and enter into the mitochondrial matrix to compensate for the lack of pyruvate transport under
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conditions in which MPC1 or MPC2 is not present or functional. A
clear limitation of our adipogenesis studies is that they are solely in
vitro observations. Although our findings show that the loss of MPC
expression in vitro has no effect on adipocyte development, other
in vivo studies have found that C57BL/6 mice with an adipocyte-specific loss of MPC1 had increased fatty acid oxidation, increased levels
of triglycerides in circulation, deficiencies in storage of triglycerides,
and mitochondrial damage. It also has been observed that heterozygous MPC1 knockdown mice had decreased body weight, activity, and
fat accumulation and low body shell temperatures during cold exposure (8,27).
An analysis of several mouse tissue samples revealed that MPCs were
highly expressed in BAT, heart, lung, and skeletal muscle (Figure 4).
This is an expected finding because these are all mitochondria-rich
tissues. However, it has not been reported that MPC1 and MPC2 are
more highly enriched in BAT than other mitochondria-rich tissues
(Figure 4). Because MPCs are highly enriched in BAT depots, but not
in WAT depots, we assessed whether MPCs were regulated in adipose
tissue depots during DIO. Although MPC1 was downregulated in BAT
and WAT during high-fat feeding at the mRNA level (Figure 5), MPC1
protein expression was barely detectable and not obviously changed in
the WAT of either male or female mice during high-fat feeding (data
not shown). The differences in gene and protein expression could be
due to a variety of factors, including translational rates, protein degradation rates, or a combination of both (28). However, it is a novel
finding that MPC gene and protein expression is downregulated in
BAT of male mice, but not female, during DIO (Figures 5,6). It was
reported that reductions in diet-induced thermogenesis contributed
to weight gain after consumption of high-fat meals (29). In addition,
glucose oxidation rates were significantly decreased in individuals
after consuming high-fat meals (29). This literature suggests that the
decreased MPC expression correlated with decreased diet-induced
thermogenesis that occurs with prolonged high-fat feeding. Also,
the sex-specific regulation of MPCs (Figure 6) is likely attributed to
sex-specific metabolic responses to high-fat feeding in C57BL/6J mice
(21). Unlike male mice, previous studies have shown that female mice
were more metabolically healthy, had reduced inflammation, and were
more insulin sensitive despite having obesity while on an HFD (20-22).
Accordingly, in our study the female mice on an HFD had 27% higher
adiposity than the male HFD-fed mice but improved glucose metabolism during an intraperitoneal GTT. Data in Figure 7 demonstrate that
decreased MPC protein levels correlate with increased adiposity and
glucose intolerance in male, but not female, mice. We speculate that
the variations in expression of MPC1 and MPC2 between male and
female mice are due to differences in metabolic health and that MPCs
are specifically regulated in BAT, but not WAT, depots in conditions of
metabolic dysfunction.
In summary, our findings demonstrate that (1) the expression of MPCs
is induced during adipocyte development but not required for adipogenesis; (2) a loss of MPC expression or activity during adipogenesis
likely promotes the activation of alternative mechanisms to compensate for the loss of pyruvate transport; and (3) MPC expression is
highly enriched in BAT but decreased as a result of high-fat feeding
or DIO. Future studies will be needed to determine which substrates
can be utilized to compensate for the loss or dysfunction of MPCs. In
addition, it is necessary to determine whether adipogenesis in BAT is
dependent on MPCs. Also, future studies will be necessary to determine whether the observed in vitro effects on adipogenesis are similar
to in vivo models. O
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